NWMP
KRYS icon

Noble Wealth Management PBC’s Krystal Biotech KRYS Stock Holding History

Noble Wealth Management PBC’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$333 Sell
1
-2
-67% -$693 ﹤0.01% 765
2026
Q2 		$1.11K Buy
+3
New +$896 ﹤0.01% 686

Other funds holding KRYS

CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
RWS
Retirement Wealth Solutions Marshfield, Wisconsin $189M AUM 13.41% 1-Year Est. Return
TC
Trust Company Manhattan, Kansas $1.15B AUM 7.83% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.66B AUM 13.15% 1-Year Est. Return

Noble Wealth Management PBC's KRYS Position: Q3 2026 in Review

Noble Wealth Management PBC reduced its Krystal Biotech (KRYS) stake by 67% in Q3 2026, selling an estimated $693 and leaving 1 share worth $333. The position accounts for ﹤0.01% of the portfolio, ranked #765.

Noble Wealth Management PBC first reported a position in KRYS in Q2 2026 and has held it in 2 quarters since. The position peaked at $1.11K in Q2 2026. 11 funds tracked by Wall St. Rank hold KRYS as of Q3 2026.

  • Noble Wealth Management PBC held 1 share of Krystal Biotech worth $333 as of Q3 2026.
  • Noble Wealth Management PBC sold 2 Krystal Biotech shares in Q3 2026, an estimated $693.
  • Krystal Biotech made up ﹤0.01% of Noble Wealth Management PBC's portfolio in Q3 2026, its #765 holding.
  • Noble Wealth Management PBC first reported a position in Krystal Biotech in Q2 2026 and has held it in 2 quarters since.
  • Noble Wealth Management PBC's Krystal Biotech position peaked at $1.11K in Q2 2026.
  • 11 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2026.

Based on Noble Wealth Management PBC's 13F filing for Q3 2026, filed 1 Oct 2026.